ANEB Stock Overview
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Anebulo Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.90 |
| 52 Week High | US$4.05 |
| 52 Week Low | US$1.62 |
| Beta | -1 |
| 1 Month Change | 1.05% |
| 3 Month Change | 12.62% |
| 1 Year Change | 28.89% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -59.15% |
Recent News & Updates
Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Deliver On Growth Plans?
Feb 18
Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Invest In Growth?
Jul 03Recent updates
Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Deliver On Growth Plans?
Feb 18Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Invest In Growth?
Jul 03Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth
Mar 07We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Can Afford To Drive Business Growth
Nov 19Anebulo Pharmaceuticals to launch private investment in public equity financing
Sep 26Anebulo Pharmaceuticals GAAP EPS of -$0.10 misses by $0.03
Sep 09Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation
Jun 28Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth
Mar 15Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation
Nov 04Anebulo Pharmaceuticals reports FQ3 results
Jun 21Shareholder Returns
| ANEB | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 7.0% | 0.3% | 2.2% |
| 1Y | 28.9% | 9.8% | 22.8% |
Return vs Industry: ANEB exceeded the US Pharmaceuticals industry which returned 9.8% over the past year.
Return vs Market: ANEB exceeded the US Market which returned 22.8% over the past year.
Price Volatility
| ANEB volatility | |
|---|---|
| ANEB Average Weekly Movement | 8.9% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ANEB has not had significant price volatility in the past 3 months.
Volatility Over Time: ANEB's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 2 | Richie Cunningham | www.anebulo.com |
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company’s lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is based in Lakeway, Texas.
Anebulo Pharmaceuticals, Inc. Fundamentals Summary
| ANEB fundamental statistics | |
|---|---|
| Market cap | US$71.32m |
| Earnings (TTM) | -US$10.49m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.2x
P/E RatioIs ANEB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANEB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$10.49m |
| Earnings | -US$10.49m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.40 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ANEB perform over the long term?
See historical performance and comparison